The team at Harmony Biosciences is excited to share that they have reached their enrollment goal for the Phase 3 RECONNECT trial and screening has officially closed.

A message to the Fragile X community from Dr. Kumar Budur, Chief Medical & Scientific Officer at Harmony Biosciences:

learn more

Visit the RECONNECT MyFXReserach post for more infromation:

Clinical Trial RECONNECT: ZYN002 Gel | MyFXResearch Portal (fragilex.org)

Grief and Bereavement Experiences of Children with Intellectual Disabilities

Researchers at the University of Maryland are looking to understand how children with Fragile X syndrome (FXS) and other intellectual disabilities grieve the loss of a loved one. If you are the parent or guardian of a child with FXS or another intellectual disability who has experienced the death of someone in their life when they were 5-17 years old, researchers want to talk to you.